Antidote Technologies

Executive Summary

Antidote Technologies is a digital health company that leverages an AI-powered platform to connect patients with clinical trials, addressing a critical bottleneck in drug development. Founded in 2013 and headquartered in New York, the company operates a two-sided marketplace: patients use its proprietary search engine, Match, to discover relevant trials, while sponsors (pharmaceutical firms, CROs) leverage the platform to accelerate patient recruitment. The model reduces trial enrollment timelines and costs, benefiting both parties. As clinical trials become more complex and patient-centric, Antidote is well-positioned to capture growth in the decentralized and digital trial space. However, the company faces competition from similar platforms and must continuously expand its trial database and partnerships to maintain its edge. Despite being private with limited financial disclosure, Antidote's focus on AI-driven matching and its established presence in the U.S. suggest a solid foundation for scaling internationally.

Upcoming Catalysts (preview)

• TBDMajor Pharma Partnership for Trial Recruitment60% success
• Q4 2026Expansion into Rare Disease and Oncology Trials70% success
• H2 2026FDA Guidance Encouraging Decentralized Clinical Trials50% success